Tag Archives: Madhu Kumar

Robert W. Baird Thinks Tetraphase’s Stock is Going to Recover

In a report released yesterday, Madhu Kumar from Robert W. Baird maintained a Buy rating on Tetraphase (TTPH – Research Report), with a price target of $3. The company’s shares closed yesterday at $1.60, close to its 52-week low of

B.Riley FBR Thinks Iovance Biotherapeutics Inc’s Stock is Going to Recover

In a report released today, Madhu Kumar from B.Riley FBR reiterated a Buy rating on Iovance Biotherapeutics Inc (IOVA – Research Report), with a price target of $24. The company’s shares closed yesterday at $8.80, close to its 52-week low

B.Riley FBR Keeps a Hold Rating on Dicerna Pharma (DRNA)

In a report released yesterday, Madhu Kumar from B.Riley FBR reiterated a Hold rating on Dicerna Pharma (NASDAQ: DRNA), with a price target of $13.50. The company’s shares opened today at $13.67. Kumar wrote: “This morning, 10/29/2018, Dicerna Pharmaceuticals (DRNA)

Eiger Biopharmaceuticals (EIGR) Gets a Buy Rating from B.Riley FBR

In a report released yesterday, Madhu Kumar from B.Riley FBR reiterated a Buy rating on Eiger Biopharmaceuticals (NASDAQ: EIGR), with a price target of $21. The company’s shares opened today at $11.20. Kumar wrote: “This morning, 10/22/2018, Eiger BioPharmaceuticals (EIGR)

Eiger Biopharmaceuticals (EIGR) Received its Third Buy in a Row

After Ladenburg and Piper Jaffray gave Eiger Biopharmaceuticals (NASDAQ: EIGR) a Buy rating last month, the company received another Buy, this time from B.Riley FBR. Analyst Madhu Kumar reiterated a Buy rating on Eiger Biopharmaceuticals today and set a price

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Supernus Pharmaceuticals (NASDAQ: SUPN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (NASDAQ:ALNY) and Supernus Pharmaceuticals (NASDAQ:SUPN) with bullish sentiments. Alnylam Pharma (ALNY) B.Riley FBR analyst Madhu Kumar reiterated a Buy rating